Navigation Links
CoreValve Announces That More Than 1,800 High-Risk Patients Have Been Treated with its ReValving System for Percutaneous Aortic Valve Replacement (PAVR) : Highly encouraging registry data also presented at TCT 2008
Date:10/13/2008

CoreValve (www.corevalve.com) announced today that the expanded clinical evaluation of its ReValving System for percutaneous aortic valve replacement (PAVR) in high-risk patients with aortic stenosis continues to enroll patients at an accelerating pace. More than 1,800 patients have now been treated worldwide at nearly 100 centers in 20 countries.

IRVINE, Calif. (Business Wire EON) October 13, 2008 -- During the Monday Transcatheter Aortic Valve Replacement sessions at TCT 2008 meeting in Washington, D.C., CoreValve investigators and physician proctors presented clinical data on the subset of patients that are included in the company's post CE-Mark expanded clinical evaluation registry. Patients enrolled in the registry had a predicted 30-day mortality rate of about 23% as measured by the logistical EuroScore. By contrast, the survival rate at one-month post-procedure follow-up for these high-risk and often inoperable octogenarian registry patients was about 90%. Quality of life improvement, as measured by the New York Heart Association (NYHA) functional classification, was significantly improved as well. Follow-up on patients that are now one year post procedure demonstrate good longer term valve function and sustained survival and quality of life benefits. CoreValve believes that complications including neurological events are comparable to traditional aortic valve surgery although there is a modest, but clinically acceptable increase in pacemaker dependency in PAVR patients.

"The growing volume of very positive clinical data from an ever increasing number of physicians is most satisfying," said Eberhard Grube MD, Chief of Cardiology at the HELIOS Heart Center Siegburg, Germany. "In the hands of an experienced user, use of the CoreValve ReValving System is fast becoming a routine alternative for high risk patients suffering from severe aortic stenosis."

"We are highly encouraged by the clinical data from outside the United States that was presented at TCT," added Daniel T. Lemaitre, President and CEO of CoreValve. "Additionally, we continue to see strong sequential growth in procedure volume as 2008 unfolds; a testimony to the significant patient population whom we believe will benefit from our groundbreaking technology."

About CoreValve

CoreValve, Inc., is headquartered in Irvine, Calif. Its proprietary ReValving System allows both percutaneous aortic valve replacement (PAVR) and transapical aortic valve replacement (TAVR) and is intended to provide an alternative to open-heart surgery. The ReValving System procedures are performed on the beating heart without cardiac assistance or rapid pacing, and may result in less trauma to the patient. This technology may also offer substantial cost-savings to the healthcare system. The catheter-based technology includes a proprietary framed/self-expanding tissue heart valve that is specifically designed and engineered for transcatheter delivery. For more information about CoreValve, visit the Company's Web site at www.corevalve.com.

(Caution: the CoreValve ReValving System will not be available in the USA for clinical trials or for sale until further notice.)

Read the full story at http://www.prweb.com/releases/aortic_valve/valve_replacement/prweb1466554.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Edwards Lifesciences Initiates Patent Infringement Litigation Against CoreValve in the U.S.
2. RF Technologies(R) Announces Code Alert(R) Integrated Care Management Solution
3. CIO Healthcare Summit Announces Dates and VIP Delegates
4. Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region
5. HealthSouth Announces Plans to Build New Hospital in Arizona
6. Life Spine Announces Acquisition of Intellectual Property
7. Robbins & Myers Announces Regular Quarterly Cash Dividend
8. Boston Scientific Announces Third Quarter Adjustments
9. U.S. Department of Labor announces $1.2 million grant to provide nearly 700 North Carolina workers with health insurance payments as part of Trade Adjustment Assistance benefits
10. Vyta Corp Announces Engagement of Dr. Nino Sorgente as Independent Consultant
11. Disaboom Announces Preliminary Third Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 CoreValve Announces That More Than 1,800 High-Risk Patients Have Been Treated with its ReValving System for Percutaneous Aortic Valve Replacement (PAVR) :  Highly encouraging registry data also presented at TCT 2008 
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
(Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
Breaking Medicine Technology: